Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cerliponase Alfa · Brineura, BMN-190

Recombinant protein · Protein replacement · developed by Biomarin Pharm

Approved FDA, Apr 2017
BMRN Developer
2 Registered trials

What is Cerliponase Alfa?

Cerliponase alfa is a recombinant human tripeptidyl peptidase-1 enzyme, a proenzyme taken up by CNS cells and delivered to lysosomes via the cation-independent mannose-6-phosphate receptor, where it is activated. It replaces the deficient enzyme in CLN2 disease, a neurodegenerative lysosomal storage disorder, and is studied in patients with CLN2 disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Brineura, BMN-190
Drug type
Recombinant protein
Mechanism
Protein replacement
Pathways
lysosomal catabolism of polypeptides, CI-MPR-mediated lysosomal uptake
Therapy area
Neurology
Developer
Biomarin Pharm (BMRN)
FDA status
Approved as Brineura (April 27, 2017), BLA761052 · FDA label
UNII
X8R2D92QP1

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 5, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02678689 Phase 2 Jansky-Bielschowsky Disease Completed BMRN
NCT04476862 N/A Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 Active not recruiting BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Batten DiseaseCLN2 DiseaseCLN2 DisorderJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2

More from Biomarin Pharm

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.

Follow BMRN, the company behind Cerliponase Alfa

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.